Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 21:38:47-52.
doi: 10.1016/j.ctro.2022.10.006. eCollection 2023 Jan.

Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results

Affiliations

Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results

Marie-Eve Chand-Fouché et al. Clin Transl Radiat Oncol. .

Abstract

Background and purpose: Breast intra operative radiation therapy has been evaluated with different systems delivering 20-21 Gy with treatment times around 30 min. Papillon + TM Contact X-ray machine was designed to produce a 50 kVp beam with a high dose rate ≥ 15 Gy/minute. A pilot study with the first prototype was conducted in Nice.

Materials and methods: The inclusion criteria were age ≥ 60 years, unifocal ductal breast adenocarcinoma ≤ 2.5 cm, grade 1-2. Surgical local excision with sentinel node dissection was performed and the applicator was placed in the tumor bed after excision with a prescribed dose of 20 Gy. The main end point of the study was the doses measured with the Gafchromic films; two were located at the skin surface and two in the excision cavity. Secondary endpoints were early toxicity and relapse free survival.

Results: Between 10/2018 and 09/2019, 26 patients were included. Mean Gafchromic doses were 18.8 Gy ± 2 Gy at the south pole, 15.6 Gy ± 2.81 Gy at the equator and 2.5 Gy ± 1.67 Gy at the skin. With a median follow-up time of 12 months, no skin or subcutaneous toxicity > grade 2, no local relapse and no metastasis were observed.

Conclusion: This is the first phase II study testing the Papillon + tm system for breast IORT with in vivo dosimetry measurements and reassuring clinical data.

Keywords: Brachytherapy; Breast IORT; High dose rate; Papillon+ system.

PubMed Disclaimer

Conflict of interest statement

Pr J-P Gérard declares he is medical advisor without any financial conflict for Ariane and Clerad. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
The Papillon +tm unit with the X-ray tube (black arrow) mounted at the end of the X-ray generator.Schematic sketch of the X-ray tube (micronode tm) of the Papillon+ tm unit. The tungsten anode is at the outside end of the tube providing an isotropic beam of 310°. A mineral oil cooling fluid is circulating around the X-ray tube and the anode allowing a high dose rate close to 20 Gy/ minute at the applicator surface.
Fig. 2
Fig. 2
Percentage depth dose profiles for all applicator sizes measured with Gafchromic EBT3 film NBA: Nice Breast Applicator (diameter).
Fig. 3
Fig. 3
Schematic artist representation of the dose measured using gafchromic film. It can be seen that the dark blue area (receiving between 20 and 11 Gy is irregular (irregular mammary gland cavity after tumor local excision). The dose measured close to the applicator, depending on this irregularity and close contact of the gafchromic film, can vary between 20 Gy (south pole) and 13 Gy. (equator right). This mammary gland surface dose inhomogeneity has no impact on the dose between 5 and 10 mm depth (clear blue area) which is always between 10 and 7 Gy. The mean dose to this volume of tissue is around 12 Gy with little variation for the same applicator diameter. This mean dose is larger with the 4.5 cm diameter applicator than with the 3.5 cm. In this sketch the applicator diameter is 4 cm. The irradiated volume (dark and clear blue) is close to 40 cm3 (14 % of the sphere on the north pole receiving no dose). As the two gafchromic films positioned at the skin surface close to the surgical incision are at>1 cm from the applicator surface they receive a small dose close to 2 or 3 Gy in one minute. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

References

    1. Hughes K.S., Schnaper L.A., Bellon J.R., Cirrincione C.T., Berry D.A., McCormick B., et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31(19):2382–2387. doi: 10.1200/JCO.2012.45.2615. Epub 2013 May 20PMID: 23690420. - DOI - PMC - PubMed
    1. Fastner G., Sedlmayer F., Widder J., Metz M., Geinitz H., Kapp K., et al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.nEur. J Cancer. 2020 Mar;127(12–20) doi: 10.1016/j.ejca.2019.11.024. Epub 2020 Jan 18. - DOI - PubMed
    1. Smith B.D., Arthur D.W., Buchholz T.A., Haffty B.G., Hahn C.A., Hardenbergh P.H., et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int J Radiat Oncol Biol Phys. 2009;74(4):987–1001. - PubMed
    1. Correa C1, Harris EE2, Leonardi MC3, Smith BD4, Taghian AG5, Thompson AM et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79. 10.1016/j.prro.2016.09.007. Epub 2016 Sep 17. - PubMed
    1. Polgár C., Van Limbergen E., Pötter R., Kovács G., Polo A., Lyczek J., et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) Radiother Oncol. 2010 Mar;94(3):264–273. doi: 10.1016/j.radonc.2010.01.014. Epub 2010 Feb 22. - DOI - PubMed

LinkOut - more resources